The main advantages for the PainMonitor device:

  • The PainMonitor device from MedStorm Innovation has applications for pain and nociceptive assessment for all age groups, for awakening, for regional nerve block and for withdrawal symptoms.
  • Validated in more than 70 peer reviewed clinical studies, all showing that the index increases during pain and nociceptive stimuli, and may predict painful events more sensitively and specifically than other available tools in all age groups. Moreover, the index decreases when analgesia is given. The index reacts within seconds, has low variation between and within individuals. Due to the fact that the active nerve transmitter is acetylcholine acting on muscarinic receptors, the indices are not influenced from temperature (22 °C – 42 °C), neuromuscular blockers, anxiety, the hypotensive effect of alfa-2 agonists or the circulatory influence from epinephrines or beta-blockers, as well as general hypoxia or changes in blood volume. Additionally, the Skin Conductance Algesimeter has a sensitivity more than 50 times higher than other available skin conductance devices.
  • The Skin Conductance Algesimeter is the perfect device to meet the challenges of the opioid epidemic when alfa-2 agonists, beta-blockers and regional nerve block are used. The hypotensive effect of alfa-2 agonists and the blood circulatory effect of beta-blockers do not influence the Algesimeter. The regional nerve block will be assessed within seconds by the nerve block application.
  • The device is CE-certified and approved by the authorities in Russia, soon approved by FDA and by the Ministry of Health in Israel. CMS reimbursement coding is identified.
  • PainMonitor™ is protected by eight granted patents and five pending patents.
  • There is substantial supporting scientific documentation (360 publications on the method) in anesthesia, intensive care, postoperative care, and pre-term infants: more than 10.000 patients have been monitored over 11 years, across Europe, US and Australia.
  • MedStorm Innovation has succeeded in among others three European Committee grants; Eurostars in 2011 and Seal of excellence in 2016, as well as receiving several grants from Innovation Norway. In 2018 Eurostars grant, “E!11594 – Pain and Outcome Sensor”, was obtained (top 10% of the applications) to develop wireless, miniaturized and wearable skin conductance sensors for commercial sale to assess pain, nociceptive stimuli, regional nerve-block and withdrawal symptoms.
  • The MedStorm software can be installed on the PhilipsMX patient monitor with iPC, the Philips Intellevue, the Mindray patient monitor with iView and the bridge-solution (in process), and works on the Draeger Explorer (USB ports as it is basically a flat panel PC), and some Nihon Koden patient monitors. There is a stand alone monitor available.
  • MedStorm Innovation is developing a wireless, miniaturized and wearable skin conductance sensor suited to use for the different applications.
  • The competitors, Medasense, Metrodoloris and GE (SurgicalStress Index) have all indices based on changes in blood circulation which are not as sensitive and specific to nociceptive stimuli as the Skin Conductance Algesimeter device (e.g. in circulatory unstable patients). Moreover, none of these competitors have several applications and a wireless, miniaturized and wearable sensor under development.

All indices in one PainMonitor device:

The PainMonitor index – Skin Conductance Algesimeter Index mirrors how often the skin sympathetic nerves are firing to tailor the need of analgesia during pain, nociceptive stimuli and withdrawal symptoms.

The Awakening Index mirrors how forceful the skin sympathetic nerves are firing to tailor the need of hypnotics and analgesia when the patient is waking up from sedation.

The NerveBlock Index assesses when the thin unmyelinated skin sympathetic nerves are blocked by regional anaesthesia within seconds